

**Proposed Project Scope**

# Tofacitinib for Juvenile Idiopathic Arthritis (JIA)

Date: May 2025

## Background and Rationale

CDA-AMC received a request from public drug programs for a Non-Sponsored Reimbursement Review of tofacitinib for Juvenile Idiopathic Arthritis (JIA)

**Table I: Policy Questions**

Item	Policy Question
1	Should tofacitinib be reimbursed for Juvenile Idiopathic Arthritis (JIA)?

**Table II: Products Available in Canada**

Product	Manufacturer
Tofacitinib	n/a

## Project Description

**Table III: Project Scope**

Criteria	Description
<b>Population</b>	Paediatric patients (2 -18 years) with juvenile idiopathic arthritis: <ul style="list-style-type: none"><li>• Extended oligoarthritis</li><li>• Polyarthritis (RF+)</li><li>• Polyarthritis (RF-)</li><li>• Systemic JIA without active systemic features</li><li>• Psoriatic arthritis</li><li>• Enthesitis-related arthritis</li></ul>
<b>Intervention(s)</b>	Tofacitinib
<b>Comparators</b>	<ul style="list-style-type: none"><li>• Placebo</li><li>• Nonsteroidal Anti-inflammatory Drugs (NSAIDs)</li><li>• Glucocorticoids (e.g. prednisone, triamcinolone acetonide)</li><li>• Conventional synthetic DMARDs (e.g., methotrexate, leflunomide, sulfasalazine, calcineurin inhibitors)</li><li>• Biologic disease-modifying antirheumatic drug (DMARD)<ul style="list-style-type: none"><li>○ Tumour necrosis factor blockers (adalimumab, etanercept, infliximab, golimumab, certolizumab pegol)</li><li>○ Other biologic response modifiers (abatacept, tocilizumab, anakinra, canakinumab)</li></ul></li></ul>
<b>Outcomes</b>	Clinical Effectiveness (e.g., JIA flare rate, JIA disease activity, JIA-American College of Rheumatology (ACR)70/90 criteria, Arthritis Disease Activity Score (JADAS))  Patient-reported outcomes (e.g., health-related quality of life)  Safety outcomes (e.g., harms, adverse events (AEs), serious adverse events (SAEs), discontinuations due to AEs, mortality)

**Table IV: Research Questions**

Item	Research Question
1	What is the effectiveness of tofacitinib for Juvenile Idiopathic Arthritis (JIA)?
2	What are the harms associated with tofacitinib for JIA?
3	What is the expected cost of tofacitinib for JIA vs other reimbursed regimes?

## Key Project and Protocol Components

This project will follow the [Procedures for Non-Sponsored Reimbursement Reviews](#).

## Status of the Document

This proposed project scope is being posted for information.